End Prescription Drug Ads Now Act
- Sponsor
- Rep. Nadler, Jerrold [D-NY-12]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jul 22, 2025
Bottom line
The bill aims to eliminate all direct-to-consumer advertising for prescription drugs in the United States by classifying drugs promoted through such means as misbranded.
What it actually does
This bill proposes to amend the Federal Food, Drug, and Cosmetic Act to prohibit direct-to-consumer advertising of prescription drugs. It would classify any drug as 'misbranded' if its manufacturer has engaged in promotional communications targeting consumers, including through television, radio, print, digital platforms, and social media, within the most recent 30-day period.
Proponents argue
Proponents argue that banning direct-to-consumer drug advertising would reduce healthcare costs by curbing demand for expensive, often brand-name drugs, and would improve prescribing practices by allowing medical professionals to make decisions based purely on patient need rather than patient requests influenced by advertising. They also contend it would protect consumers from potentially misleading or overly persuasive marketing tactics.
Opponents contend
Opponents would argue that such a ban infringes on the First Amendment rights of drug manufacturers to engage in commercial speech and limits patients' access to important information about treatment options. They contend that direct-to-consumer ads educate consumers about new drugs and medical conditions, empowering them to have more informed discussions with their doctors.
The bill text is exceptionally short and clear, allowing for a very quick and straightforward understanding of its core proposal.
Section 2(a), amending Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352)
Prohibition on Direct-to-Consumer Drug Advertising
This provision amends existing law to declare any prescription drug 'misbranded' if its manufacturer has engaged in direct-to-consumer advertising for that drug within the preceding 30 days. This ban covers all forms of promotional communication aimed at consumers, including traditional media like TV and print, as well as digital and social media platforms, for drugs approved under section 505 or licensed under section 351 of the Public Health Service Act.
Supporters argue
Supporters argue this will reduce healthcare costs by curbing demand for expensive, often unnecessary, brand-name drugs, and allow doctors to make prescribing decisions based purely on medical need. They also contend it will protect consumers from potentially misleading or overly aggressive marketing tactics.
Critics contend
Critics contend this provision restricts the free flow of information to patients, potentially limiting their awareness of new treatments and their ability to engage in informed discussions with their doctors. They also argue it could stifle competition and innovation by making it harder for new drugs to gain market traction.
Tradeoffs
The bill balances the potential benefits of reducing drug costs and promoting evidence-based prescribing against concerns about limiting patient information access and potential impacts on pharmaceutical innovation and media revenue.